



27 October 2025

Medicine Supply Alert Notice

Mometasone (Asmanex Twisthaler®) 200micrograms/dose dry powder and 400micrograms/dose dry powder inhalers

Priority: Level 2*

Valid until: above noted products are being discontinued

Issue

1. Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (60 dose) is being discontinued from late October 2025.
2. Mometasone (Asmanex Twisthaler®) 200microgram/dose dry powder inhaler (30 dose) and 400micrograms/dose dry powder inhaler (30 dose and 60 dose) are being discontinued from late February 2026.
3. Alternative corticosteroid inhalers remain available (see Additional Information section).

Advice and Actions

4. Prescribers should:
 - not initiate new patients on Asmanex Twisthalers®;
 - identify and review existing patients prescribed an Asmanex Twisthaler® and consider appropriateness of switching to another inhaled treatment in line with Healthcare Improvement Scotland [SIGN asthma guidelines](#) (see Additional Information section); and
 - ensure that the patient is not intolerant to any of the excipients in the new inhaler, is counselled on how to use the inhaler if judged suitable for use, on the dose to be administered, and to seek advice from their prescriber if asthma worsens.
5. If the above options are not considered appropriate, advice should be sought from specialists on management options.

Additional Information

Clinical Information

6. Mometasone dry powder inhalers are licensed for the regular treatment of asthma in adults and children 12 years of age and older.

*<https://www.nss.nhs.scot/media/1842/medicine-supply-alert-notices-definitions-of-classifications-21-october-2019.pdf>

7. [SIGN asthma guidelines](#) updated in 2024 recommend that the initial management for newly diagnosed asthma in people aged 12 years and over should now be with either:
- Low-dose inhaled corticosteroid/formoterol combination to be taken as-needed (Anti-inflammatory reliever [AIR] therapy); or
 - Low-dose maintenance and reliever (MART) therapy for patients with highly symptomatic asthma (e.g. regular nocturnal waking) or with a severe exacerbation, which can be stepped down to as-needed AIR therapy, if asthma is controlled.
8. The [BNF](#) notes budesonide with formoterol is licensed for as-needed AIR therapy in mild asthma, and beclometasone with formoterol and budesonide with formoterol are licensed for MART.

Links to further information

- [BNF Chronic asthma](#)
- [SIGN 245 guideline - Asthma: diagnosis, monitoring and chronic asthma management](#)
- [SmPC Asmanex Twisthaler](#)
- [SmPCs: Budesonide-Formoterol combination inhalers](#)
- [SmPCs: Beclometasone- Formoterol combination inhalers](#)
- [Right Breathe: Budesonide+ Formoterol inhalers](#)
- [Right Breathe: Beclometasone + Formoterol inhalers](#)

Specialist Pharmacy Service (SPS) website

9. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
10. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

11. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).